{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:06:59Z","timestamp":1778846819509,"version":"3.51.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","award":["P30CA196521"],"award-info":[{"award-number":["P30CA196521"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-1- 0470"],"award-info":[{"award-number":["W81XWH-19-1- 0470"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0330"],"award-info":[{"award-number":["W81XWH-18-1-0330"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA274967"],"award-info":[{"award-number":["R01CA274967"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P01CA228696-02"],"award-info":[{"award-number":["5P01CA228696-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.celrep.2025.115779","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:38:55Z","timestamp":1748630335000},"page":"115779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways"],"prefix":"10.1016","volume":"44","author":[{"given":"Rahim","family":"Hirani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhiksha","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabila","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prathiksha","family":"Prabhakaraalva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Ann","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teja Muralidhar","family":"Kalidindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Ghale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Harisha","family":"Rajanala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah C.","family":"Fidele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"De Stanchina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwo-Shu","family":"Mary Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naga Vara","family":"Kishore Pillarsetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad H.","family":"Stopsack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Gopalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorelei A.","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Kyprianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh K.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Danila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip W.","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-2621","authenticated-orcid":false,"given":"Goutam","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2025.115779_bib1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/iju.13512","article-title":"Current treatment strategies for advanced prostate cancer","volume":"25","author":"Komura","year":"2018","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.celrep.2025.115779_bib3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2025.115779_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.celrep.2025.115779_bib8","article-title":"Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.celrep.2025.115779_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.celrep.2025.115779_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41467-023-36253-1","article-title":"Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer","volume":"14","author":"Chakraborty","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115779_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.celrep.2025.115779_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cdd.2017.188","article-title":"Bcl-2 on the brink of breakthroughs in cancer treatment","volume":"25","author":"Reed","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.celrep.2025.115779_bib14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2\u2013positive metastatic breast cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2025.115779_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib16","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1074\/jbc.275.15.10761","article-title":"Akt\/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein","volume":"275","author":"Pugazhenthi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2025.115779_bib17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.18632\/oncotarget.809","article-title":"Coordinate PI3K pathway and Bcl-2 family disruption in AML","volume":"3","author":"Bose","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2025.115779_bib18","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115779_bib19","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-18-0610","article-title":"Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations","volume":"78","author":"Sowalsky","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib21","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1200\/JCO.2008.17.2882","article-title":"Genomic strategy for targeting therapy in castration-resistant prostate cancer","volume":"27","author":"Mendiratta","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115779_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","article-title":"Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy","volume":"66","author":"Rajan","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.celrep.2025.115779_bib23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1186\/1471-2407-14-977","article-title":"Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer","volume":"14","author":"Rajan","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.celrep.2025.115779_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib26","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib28","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.115779_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.6004\/jnccn.2013.0194","article-title":"New developments in the management of prostate cancer","volume":"11","author":"Kantoff","year":"2013","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.celrep.2025.115779_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115779_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib32","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.115779_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12192-008-0095-4","article-title":"Role of Foxa1 in regulation of bcl2 expression during oxidative-stress-induced apoptosis in A549 type II pneumocytes","volume":"14","author":"Song","year":"2009","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.celrep.2025.115779_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179998","article-title":"BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity","volume":"134","author":"Westaby","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2025.115779_bib35","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models","volume":"106","author":"Caldas-Lopes","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.115779_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib37","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.115779_bib38","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.115779_bib39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","article-title":"Regulation of mTORC1 by PI3K signaling","volume":"25","author":"Dibble","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.celrep.2025.115779_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2025.115779_bib41","doi-asserted-by":"crossref","first-page":"38830","DOI":"10.1074\/jbc.M103632200","article-title":"PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression","volume":"276","author":"Huang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2025.115779_bib42","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-21-4272","article-title":"The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer","volume":"28","author":"Chakraborty","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib43","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2025.115779_bib44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2025.115779_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110595","article-title":"Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis","volume":"39","author":"Han","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2025.115779_bib47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115779_bib48","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12885-015-1485-5","article-title":"Constitutive expression of Bcl-2 induces epithelial-Mesenchymal transition in mammary epithelial cells","volume":"15","author":"An","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.celrep.2025.115779_bib49","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib50","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/nm.2473","article-title":"A crucial requirement for Hedgehog signaling in small cell lung cancer","volume":"17","author":"Park","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib51","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41416-020-01220-w","article-title":"Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study","volume":"124","author":"Verkouteren","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2025.115779_bib52","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41467-018-06067-7","article-title":"Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115779_bib53","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1158\/0008-5472.CAN-21-3552","article-title":"The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response","volume":"82","author":"Berchuck","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106320","article-title":"Potential role of Bcl2 in lipid metabolism and synaptic dysfunction of age-related hearing loss","volume":"187","author":"Liu","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.celrep.2025.115779_bib55","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/jcb.21343","article-title":"BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer","volume":"102","author":"Mortenson","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.celrep.2025.115779_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","article-title":"Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells","volume":"21","author":"Muranen","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib57","article-title":"Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment","volume":"43","author":"Hamid","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.celrep.2025.115779_bib58","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115779_bib59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JCO.2023.41.6_suppl.182","article-title":"Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Perimbeti","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115779_bib60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2023-179541","volume":"142","author":"Tam","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2025.115779_bib61","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib62","article-title":"De Bono Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Zhen Shi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115779_bib63","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and Biological Features of Neuroendocrine Prostate Cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.celrep.2025.115779_bib65","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature02962","article-title":"Hedgehog signalling in prostate regeneration, neoplasia and metastasis","volume":"431","author":"Karhadkar","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115779_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2016.04.014","article-title":"A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer","volume":"99","author":"Pietanza","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.celrep.2025.115779_bib67","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1158\/1078-0432.CCR-22-3736","article-title":"Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors","volume":"29","author":"Menssouri","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib68","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ncb3616","article-title":"Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor","volume":"19","author":"Wu","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.celrep.2025.115779_bib69","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/01.ju.0000055140.91204.c7","article-title":"Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells","volume":"169","author":"Bruckheimer","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.celrep.2025.115779_bib70","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1530\/ERC-12-0285","article-title":"Current mouse and cell models in prostate cancer research","volume":"20","author":"Wu","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.celrep.2025.115779_bib71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.celrep.2025.115779_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301989","article-title":"Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting","volume":"19","author":"Rajanala","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2025.115779_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2025.115779_bib75","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-18-1669","article-title":"CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets","volume":"78","author":"Cortazar","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115779_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","article-title":"ONCOMINE: a cancer microarray database and integrated data-mining platform","volume":"6","author":"Rhodes","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.celrep.2025.115779_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2016.06.009","article-title":"Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling","volume":"166","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.115779_bib78","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2025.115779_bib79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.celrep.2025.115779_bib80","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-20-2483","article-title":"Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725005509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725005509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:10:28Z","timestamp":1778843428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124725005509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2211124725005509"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2025.115779","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2025.115779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115779"}}